EP Patent

EP2130537A1 — N3 alkylated benzimidazole derivatives as mek inhibitors

Assigned to Array Biopharma Inc · Expires 2009-12-09 · 16y expired

What this patent protects

6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, or pharmaceutical compositions thereof for use in the inhibition of abnormal cell growth.

USPTO Abstract

6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, or pharmaceutical compositions thereof for use in the inhibition of abnormal cell growth.

Drugs covered by this patent

selumetinib-sulfate (SELUMETINIB SULFATE)

Patent Metadata

Patent number: EP2130537A1
Jurisdiction: EP
Classification: —
Expires: 2009-12-09
Drug substance claim: No
Drug product claim: No
Assignee: Array Biopharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.